Mathematical models of cancer dormancy
暂无分享,去创建一个
[1] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[2] J. Uhr,et al. Monoclonal antibodies as agonists: an expanded role for their use in cancer therapy. , 1994, Cancer research.
[3] Nicola Bellomo,et al. A Survey of Models for Tumor-Immune System Dynamics , 1996 .
[4] R. Woodland,et al. Naive B Lymphocytes Undergo Homeostatic Proliferation in Response to B Cell Deficit1 , 2002, The Journal of Immunology.
[5] G. D. Knott,et al. Modeling tumor regrowth and immunotherapy , 2001 .
[7] A. George,et al. Idiotypic vaccination as a treatment for a B cell lymphoma. , 1988, Journal of immunology.
[8] L. Preziosi,et al. Modelling and mathematical problems related to tumor evolution and its interaction with the immune system , 2000 .
[9] R. Schreiber,et al. Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.
[10] A. McLean,et al. Resource competition as a mechanism for B cell homeostasis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[11] J. Uhr,et al. Cancer dormancy: studies of the murine BCL1 lymphoma. , 1991, Cancer research.
[12] S. Eccles,et al. Immunologically-mediated restraint of latent tumour metastases , 1975, Nature.
[13] R. Scheuermann,et al. Tumour dormancy and cell signalling--III: Role of hypercrosslinking of IgM and CD40 on the induction of cell cycle arrest and apoptosis in B lymphoma cells. , 1995, Therapeutic immunology.
[14] R. Scheuermann,et al. Cancer dormancy: Opportunities for new therapeutic approaches , 1997, Nature Medicine.
[15] M. Nowak,et al. Oncogenes, anti-oncogenes and the immune response to cancer : a mathematical model , 1992, Proceedings of the Royal Society of London. Series B: Biological Sciences.
[16] Stuart H. Orkin,et al. Diversification of haematopoietic stem cells to specific lineages , 2000, Nature Reviews Genetics.
[17] P. Isakson,et al. BCL1, a Murine Model for Chronic Lymphocytic Leukemia: Use of the Surface Immunoglobulin Idiotype for the Detection and Treatment of Tumor , 1979, Immunological reviews.
[18] J. Uhr,et al. Tumor dormancy. I. Regression of BCL1 tumor and induction of a dormant tumor state in mice chimeric at the major histocompatibility complex. , 1986, Journal of immunology.
[19] P. Hahnfeldt,et al. Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. , 1999, Cancer research.
[20] Lars Holmgren,et al. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.
[21] L. Picker,et al. Lymphocyte Homing and Homeostasis , 1996, Science.
[22] J A Sherratt,et al. Modelling the macrophage invasion of tumours: effects on growth and composition. , 1998, IMA journal of mathematics applied in medicine and biology.
[23] A Romano,et al. Analysis of a "phase transition" from tumor growth to latency. , 2000, Physical review. E, Statistical physics, plasmas, fluids, and related interdisciplinary topics.
[24] R. Scheuermann,et al. Tumor dormancy and cell signaling. II. Antibody as an agonist in inducing dormancy of a B cell lymphoma in SCID mice , 1995, The Journal of experimental medicine.
[25] B. Fisher,et al. Experimental Evidence in Support of the Dormant Tumor Cell , 1959, Science.
[26] R. Miller,et al. Therapy of lymphoma directed at idiotypes. , 1990, Journal of the National Cancer Institute. Monographs.
[27] J. Folkman,et al. Angiostatin induces and sustains dormancy of human primary tumors in mice , 1996, Nature Medicine.
[28] B. Rocha,et al. Population biology of lymphocytes: the flight for survival. , 2000, Annual review of immunology.
[29] Y. W. Huang,et al. Tumor dormancy and cell signaling. V. Regrowth of the BCL1 tumor after dormancy is established. , 1997, Blood.
[30] F. Stevenson,et al. Preliminary experience in treating lymphocytic leukaemia with antibody to immunoglobulin idiotypes on the cell surfaces. , 1980, British Journal of Cancer.
[31] D. P. Cooney,et al. Spontaneous regression of non‐Hodgkin's lymphoma: A report of nine cases , 1980, Cancer.
[32] G. Riethmüller,et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma , 1994, The Lancet.
[33] R. Scheuermann,et al. Cancer dormancy. VII. A regulatory role for CD8+ T cells and IFN-gamma in establishing and maintaining the tumor-dormant state. , 1999, Journal of immunology.
[34] D. Wilbur,et al. Malignant Melanoma with Delayed Metastatic Growths , 1931 .
[35] S. Strober,et al. Spontaneous murine B-cell leukaemia , 1978, Nature.
[36] G. Hadfield. The Dormant Cancer Cell* , 1954, British medical journal.
[37] A. Perelson,et al. Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis. , 1994, Bulletin of mathematical biology.
[38] J. Marx. Monoclonal antibodies in cancer. , 1982, Science.
[39] A. Ullrich,et al. Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic , 1991, Journal of Clinical Immunology.
[40] H M Byrne,et al. The effect of time delays on the dynamics of avascular tumor growth. , 1997, Mathematical biosciences.
[41] R. Kerbel. Monoclonal Antibodies in Cancer Therapy: An Overview , 1999, Cancer and Metastasis Reviews.
[42] Thomas Boehm,et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance , 1997, Nature.
[43] A. George,et al. Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1. , 1987, Journal of immunology.
[44] P. Nowell. The clonal evolution of tumor cell populations. , 1976, Science.
[45] H. Modjtahedi,et al. Differentiation or immune destruction: two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor. , 1994, Cancer research.
[46] Y. Moshel,et al. Tumor‐cell vaccination induces tumor dormancy in a murine model of B‐cell leukemia/lymphoma (BCL1) , 1996, International journal of cancer.